Using defective lipoylation as a window into cardiac fuel consumption and failure

Active Project Grant Awarded Last action

Award ID
F32HL174084
Recipient
Awarding agency
Obligated
$320,188

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 69% complete
Place of performance
Dallas, TX 75390, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Metabolism is essential for normal cellular function and dynamically changes to meet organism and tissue needs. Cardiac function and metabolism are closely intertwined. Fatty acid oxidation serves as the primary means to provide energy in normal conditions. In heart failure, cardiomyocytes lose this metabolic flexibility and become more reliant on glycolysis. Despite extensive work to understand the metabolic underpinnings of heart failure, more investigation is needed to dissect the underlying mechanisms of this disease. A class of metabolic diseases collectively known as inborn errors of metabolism (iems) provide a window into pathophysiology, including heart failure, due to their well-defined causes. Pathology arising from iems can be tracked back to a single mutation, providing a direct and tractable method of studying the disease. Lipoic acid deficiencies are a novel class of iems that cause metabolic decompensation, severe neurodevelopmental delays, and early death. Lipoyltransferase-1 (LIPT1) catalyzes the final step in DE novo lipoic acid synthesis by transferring the lipoate moiety to 2-ketoacid dehydrogenases such as pyruvate dehydrogenase (PDH), oxoglutarate dehydrogenase (ogdh), and branched-chain ketoacid dehydrogenase (bckdh). The genetic and metabolic disease program (gmdp) at UT southwestern has unique access to patient samples and clinical data. A LIPT1 deficient patient presented with neurodevelopmental delays and numerous unexpected metabolic phenotypes, including elevated serum 2-hydroxyglutarate (2HG), a metabolite with wide ranging impacts on cell signaling and epigenetic regulation. The patient also displayed altered cardiac function, including impaired systolic function and tachycardia secondary to atrial fibrillation, worsened by acute episodes of metabolic decompensation. We intend to characterize the underlying causes of cardiometabolic distress using novel mice to model cardiac LIPT1 deficiency. Mice lacking LIPT1 in the heart DIE within 6-7 weeks with severe systolic dysfunction and elevated levels of 2HG. The central hypothesis of this proposal is that LIPT1 deficiency pathologically limits cardiometabolic flexibility leading to deleterious metabolite accumulation, including 2HG, and impaired cardiac development and function. If successful, this proposal will generate a definitive assessment of cardiac LIPT1 deficiency in mice providing a detailed understanding of the metabolic consequences of this specific IEM. More broadly, this proposal will increase our understanding of the consequences of limited metabolic flexibility in cardiac tissue, a hallmark of heart failure. The appropriate usage of both patient data and mouse models will increase the disease relevance of the work discussed in this proposal.

Transactions

Action Obligated Date
Amendment $84,580
Amendment $81,040
Amendment $77,284
Amendment $0
Original award $77,284

Quick answers

Who received award F32HL174084?

F32HL174084 was awarded to The University Of Texas Southwestern Medical Center by National Heart Lung and Blood Institute (National Institutes of Health) on December 17, 2024.

How much is award F32HL174084 worth?

$320,188 has been obligated on F32HL174084.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login